A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

被引：0
|
作者：
Tara L. Lin
Laura F. Newell
Robert K. Stuart
Laura C. Michaelis
Eric Rubenstein
Helen S. Pentikis
Timothy Callahan
Donna Alvarez
Barry D. Liboiron
Lawrence D. Mayer
Qi Wang
Kamalika Banerjee
Arthur C. Louie
机构：
[1] University of Kansas Medical Center,Hollings Cancer Center
[2] Knight Cancer Institute,undefined
[3] Oregon Health and Science University,undefined
[4] Medical University of South Carolina,undefined
[5] Medical College of Wisconsin,undefined
[6] Oncology and Hematology Specialists,undefined
[7] Franciscan Health,undefined
[8] SAJE Consulting,undefined
[9] Biomedical Systems,undefined
[10] Celator/Jazz Pharmaceuticals,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Acute myeloid leukemia; Acute lymphoblastic leukemia; Cardiac repolarization; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：163 / 173
页数：10
相关论文
共 50 条
  • [31] A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia
    Absalon, Michael J.
    Breese, Erin H.
    Lee, Lynn
    O'Brien, Maureen M.
    Phillips, Christine L.
    Burns, Karen
    Mizukawa, Benjamin
    An, Qi
    Mangino, Jennifer
    Kaplan, Joel
    Norris, Robin
    Perentesis, John Peter
    BLOOD, 2018, 132
  • [32] A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3
    Price, Kwanza
    Cao, Zhun
    Lipkin, Craig
    Robinson, Scott
    Profant, Deborah Ann
    BLOOD, 2019, 134
  • [33] Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Croden, Jennifer
    Hammond, Danielle
    Chien, Kelly S.
    Maiti, Abhishek
    Tippett, George Donovan
    Montalban-Bravo, Guillermo
    Morales, Michael
    Short, Nicholas J.
    Abbas, Hussein A.
    Issa, Ghayas C.
    Kadia, Tapan M.
    Borthakur, Gautam
    Ravandi, Farhad
    Dinardo, Courtney D.
    BLOOD, 2024, 144 : 4271 - 4272
  • [34] Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies
    Lancet, Jeffrey E.
    Ritchie, Ellen K.
    Uy, Geoffrey L.
    Medeiros, Bruno C.
    Newell, Laura F.
    Lin, Tara L.
    Hogge, Donna
    Stuart, Robert K.
    Strickland, Stephen A.
    Solomon, Scott R.
    Stone, Richard M.
    Kolitz, Jonathan E.
    Bixby, Dale L.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Kovacsovics, Tibor
    Ryan, Robert J.
    Chiarella, Michael
    Louie, Arthur C.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [35] Phase I study of a liposomal carrier (CPX-351) containing an optimized, synergistic, fixed molar ratio of cytarabine (Ara-C) and daunorubicin (DNR) in advanced leukemias and myelodysplastic syndromes (MDS)
    Feldman, Eric J.
    Lancet, Jeffrey E.
    Kolitz, Jonathan E.
    Asatiani, Ekatherine
    Curcio, Tania J.
    Burton, Michelle K.
    Fricano, Marjorie
    Begley, Aman R.
    Swenson, Christine
    Mayer, Lawrence
    Janoff, Andrew S.
    Louie, Arthur C.
    BLOOD, 2007, 110 (11) : 274A - 275A
  • [36] A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study
    Wierzbowska, Agnieszka
    Pluta, Agnieszka
    Stelmach, Piotr
    Brzozowski, Kamil
    Czemerska, Magdalena
    Sobas, Marta
    Rybka, Justyna
    Wrobel, Tomasz
    Zarzycka, Ewa
    Prejzner, Witold
    Zaucha, Jan M.
    Szczepaniak, Andrzej
    Gil, Lidia
    Giebel, Sebastian
    BLOOD, 2023, 142
  • [37] V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia
    Lin, Tara
    Mannis, Gabriel N.
    Erba, Harry P.
    Levis, Mark
    Zou, Heng
    Faderl, Stefan
    Cheung, Ronald S.
    Pullarkat, Vinod A.
    BLOOD, 2020, 136
  • [38] Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents
    Montalban-Bravo, Guillermo
    Jabbour, Elias
    Chien, Kelly S.
    Borthakur, Gautam
    Estrov, Zeev
    Kadia, Tapan M.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Nogueras-Gonzalez, Graciela
    Schneider, Heather
    John, Rosmy
    Meyer, Meghan Anne
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Dong, Xiao Qin
    BLOOD, 2023, 142
  • [39] Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents
    Montalban-Bravo, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Ravandi, Farhad
    Chien, Kelly
    Pemmaraju, Naveen
    Hammond, Danielle
    Dong, Xiao Qin
    Huang, Xuelin
    Schneider, Heather
    John, Rosmy
    Kanagal-Shamana, Rashmi
    Loghavi, Sanam
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (03) : 898 - 909
  • [40] Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients 60-75 Years of Age with Secondary Acute Myeloid Leukemia
    Larson, Melissa L.
    Rubenstein, S. Eric
    Schiller, Gary J.
    Solomon, Scott R.
    Louie, Arthur C.
    Paulsen, Kim H.
    Lin, Tara L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S208 - S209
12345